| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/12/2004 | US20040029123 Diagnosis of diseases associated with the cell cycle |
| 02/12/2004 | US20040029118 Computer readable medium having recorded thereon given nucleotide sequence; use in identifying commercially important nucleic acid fragments |
| 02/12/2004 | US20040029106 Duplexed parvovirus vectors |
| 02/12/2004 | US20040028727 Dry formulation for transcutaneous immunization |
| 02/12/2004 | US20040028700 Antigenic proteins of shrimp white spot syndrome virus and uses thereof |
| 02/12/2004 | US20040028685 EphA2 monoclonal antibodies and methods of use thereof |
| 02/12/2004 | US20040028684 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/12/2004 | US20040028669 Human gene critical to fertility |
| 02/12/2004 | US20040028660 Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| 02/12/2004 | US20040028658 Methods of organ regeneration |
| 02/12/2004 | US20040028654 Protamine-adenoviral vector complexes and methods of use |
| 02/12/2004 | US20040028653 Self-rearranging DNA vectors |
| 02/12/2004 | US20040028651 Composition and methods of using hiv vpr |
| 02/12/2004 | US20040028616 Dna-polyethylenimine complex; aerosol administering gene and anticancer agents |
| 02/12/2004 | DE10233516A1 Cellular method for identifying modulators of target molecules, useful in screening for pharmaceuticals, from effects of test compounds on both cell growth and reporter expression |
| 02/12/2004 | DE10225180A1 Protein oder Peptid (MIMPD), hierfür codierende Nukleinsäure sowie Verwendungen dieser Stoffe Protein or peptide (MIMPD), this encoding nucleic acid and uses of these substances |
| 02/12/2004 | CA2494868A1 Allele-specific sirna-mediated gene silencing |
| 02/12/2004 | CA2494859A1 Sirna-mediated gene silencing with viral vectors |
| 02/12/2004 | CA2494240A1 Maxs as modifiers of the axin pathway and methods of use |
| 02/12/2004 | CA2493752A1 Papsss as modifiers of the axin pathway and methods of use |
| 02/12/2004 | CA2492497A1 Compositions, methods, and kits relating to behab and primary cns tumors |
| 02/11/2004 | EP1387892A2 Gene delivery compounds |
| 02/11/2004 | EP1387674A2 Hedgehog antagonists, methods and uses related thereto |
| 02/11/2004 | EP0888452B1 Human cyr61, an extracellular matrix signalling molecule |
| 02/11/2004 | EP0862615B1 Immunity against pasteurella haemolytica leukotoxin |
| 02/11/2004 | EP0858467B1 Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof |
| 02/11/2004 | CN1137723C Enhanced wound coverage and composition to enhance wound healing |
| 02/10/2004 | US6690976 Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
| 02/10/2004 | US6689879 Nucleotide sequences coding nvelope protein for use in the prevention of viral diseases |
| 02/10/2004 | US6689877 Administering a therapeutic amount of nebr1 antiretroviral transcriptional factor to hiv infected cells in patient |
| 02/10/2004 | US6689866 Isolated polypeptide comprising specified amino acid sequence; membrane-bound or secreted polypeptide having semaphorin-like activity |
| 02/10/2004 | US6689775 Use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or eliminating thioredoxin-associated apoptosis inhibition and thioredoxin stimulated cell growth |
| 02/10/2004 | US6689758 Treating wounds; using an early growth response-1 transcription factor polypeptide or fragment |
| 02/10/2004 | US6689757 Methods for vaccination and vaccines therefor |
| 02/10/2004 | US6689610 Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same |
| 02/10/2004 | US6689606 Polynucleotide |
| 02/10/2004 | US6689605 Controlling immune response to specific antigens |
| 02/10/2004 | US6689600 Formulation of adenovirus for gene therapy |
| 02/10/2004 | US6689580 Growth factor |
| 02/10/2004 | US6689562 Mammalian IAP gene family, primers, probes and detection methods |
| 02/10/2004 | US6689121 Systems and methods for treating ischemia |
| 02/10/2004 | US6689090 Perfusion apparatus and methods for pharmaceutical delivery |
| 02/10/2004 | CA2274581C Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 02/09/2004 | CA2421269A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/05/2004 | WO2004011680A1 Regulated aptamer therapeutics |
| 02/05/2004 | WO2004011626A2 Assays and methods based on microcompetition with a foreign polynucleotide |
| 02/05/2004 | WO2004011624A2 Double stranded rna structures and constructs, and methods for generating and using the same |
| 02/05/2004 | WO2004011595A2 Vectors for transferring molecules of interest in target cells |
| 02/05/2004 | WO2004011489A2 Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells |
| 02/05/2004 | WO2004011486A2 Method for solubilizing hydrophobic peptides and use thereof for inducing an antitumoral and/or anti-infectious ctl response |
| 02/05/2004 | WO2004010959A2 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
| 02/05/2004 | WO2004010927A2 Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes |
| 02/05/2004 | WO2004010900A1 Devices delivering therapeutic agents and methods regarding the same |
| 02/05/2004 | WO2003097871A3 Marker molecules associated with lung tumors |
| 02/05/2004 | WO2003097089A3 Attenuation of metapneumovirus |
| 02/05/2004 | WO2003094829A3 Pathogen vaccines and methods for using the same |
| 02/05/2004 | WO2003094828A3 Cancer vaccines and methods of using the same |
| 02/05/2004 | WO2003089624A3 Fc receptor homolog, reagents, and uses thereof |
| 02/05/2004 | WO2003087818A3 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 02/05/2004 | WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 02/05/2004 | WO2003083442A3 Life sciences business systems and methods |
| 02/05/2004 | WO2003082915A3 Xcrf polynucleotides and polypeptides and uses thereof |
| 02/05/2004 | WO2003082255A3 Use of mob-5 in pain |
| 02/05/2004 | WO2003082195A9 Protamine-adenoviral vector complexes and methods of use |
| 02/05/2004 | WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 02/05/2004 | WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 02/05/2004 | WO2003052052A3 Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| 02/05/2004 | WO2003042397A3 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| 02/05/2004 | WO2003037172A3 Endothelial-cell binding peptides for diagnosis and therapy |
| 02/05/2004 | WO2002094378A3 Increased functional activity and/or expression of abc transporters protects against the loss of dopamine neurons associated with parkinson's disease |
| 02/05/2004 | WO2002061046A3 Novel nucleic acid and polypeptide molecules |
| 02/05/2004 | WO2002059373A3 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| 02/05/2004 | US20040025196 Comprises nucleotide sequences coding proteins with plenty of SH3 domains (POSH) for preventing viral and bacterial infection and replication; rational drug design; viricides; antiapoptosis agents; bactericides |
| 02/05/2004 | US20040024064 Determining risk for developing a fat metabolism disorder by comparing a sample Gs alpha expression level with that of the normal level; treating the disorder with a nucleic acid that codes a Gs alpha protein; prognosis; diagnosis; |
| 02/05/2004 | US20040023915 Tocopherol associated protein and uses thereof |
| 02/05/2004 | US20040023912 Method of diagnosis and treatment of breast lesions |
| 02/05/2004 | US20040023911 Delivering a naked or isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of a naked polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells |
| 02/05/2004 | US20040023909 Process for preventing or reducing undesirable immunological effects to infectious agents in subjects |
| 02/05/2004 | US20040023908 Antisense modulation of a20 expression |
| 02/05/2004 | US20040023903 Single-stranded end-capped oligonucleotide mediated targeted gene repair and modification and uses thereof |
| 02/05/2004 | US20040023902 Delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a |
| 02/05/2004 | US20040023885 Islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided |
| 02/05/2004 | US20040023881 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 02/05/2004 | US20040023879 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2004 | US20040023877 Plasminogen fragments containing kringle region domains having anti-angiogenic activity and terned angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases such as |
| 02/05/2004 | US20040023872 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/05/2004 | US20040023866 Isolated Bcl-2 domain-containing polypeptides from Mycobacterial species, including M. tuberculosis, M. avium, M. bovis, M. leprae and M. smegmatis, and from Streptomyces species, including S. coelicolor, as well as modifications of |
| 02/05/2004 | US20040023862 Newly identified uses of BRS3 polypeptides and polynucleotides encoding such polypeptides, to their use in therapy of ischemia, of neurodegenerative diseases, of memory and attention disorders, and in identifying compounds which may be |
| 02/05/2004 | US20040023855 Biologic modulations with nanoparticles |
| 02/05/2004 | US20040023393 Forming negatively-charged zwitterionic and/or neutral complexes for delivering genetic material into cells; reverse micelles |
| 02/05/2004 | US20040023392 Use in introducing predetermined change at predetermined location in target gene in living cell; oligodeoxynucleotide is modified by attachment of 3' and 5' blocking substituents such as a 3'-3'linked cytosine nucleotide and a 5' linked dye |
| 02/05/2004 | US20040023390 Using small interfering RNA sequences for treating neurodegenerative diseases; gene expression inhibition |
| 02/05/2004 | US20040023389 Plasmid coding proteins associated with immune response for immunotherapeutic treatment of cancer; gene therapy; anticarcinogenic agents |
| 02/05/2004 | US20040023379 Comprises oligonucleotides for gene expression inhibition of hepatoma derived growth factor (HDGF) for treating cancer and metabolic disorder |
| 02/05/2004 | US20040023356 Comprise nucleotides equences coding polypeptide for use in diagnosis and treatment of bone, eye and peridontal disease |
| 02/05/2004 | US20040023337 IL-13 mutein proteins, antibodies, compositions, methods and uses |
| 02/05/2004 | US20040023335 IL-17 like molecules and uses thereof |
| 02/05/2004 | US20040023333 Production of recombinant blood clotting factors in human cell lines |
| 02/05/2004 | US20040023332 Genes of il-12p40 subunit mutated for improving the activity of il-12 and thereof for dna vaccine adjuvant |
| 02/05/2004 | US20040023278 Sialoadhesin family member-2 (SAF-2) |